Kathy Miller
Program Leader - Breast · Indiana University School of Medicine
Credentials: · · · ·
History
- 1991–1994
Internal Medicine
Research
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
New England Journal of Medicine · 2007 · First of 9 authors · Corresponding · 2,445 citations
Journal of Clinical Oncology · 2005 · First of 12 authors · Corresponding · 1,039 citations
Systematic review or meta-analysis · Journal of the National Cancer Institute · 2007 · 745 citations
85 papers
39 papers · 1 as a fellow
31 papers
- AW
23 papers
20 papers
20 papers
19 papers
18 papers
Grants
- 2026–2032
Building upon a Tradition of Excellence. The NCTN at IUSCCC
National Cancer Institute · UG1
Contact PI · $366.9K · Indiana University Indianapolis
- 2024–2029
National Cancer Institute · U01
PI · $1M · Indiana University Indianapolis
- 1999–2024
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.7M · Indiana University Indianapolis
- 2014–2019
Building upon a Tradition of Excellence. The NCTN at Indiana University
National Cancer Institute · U10
Contact PI · $2.6M · Indiana University Indianapolis
Clinical trials
- 2024–2027
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Principal investigator · Recruiting · Phase 2
Kathy Miller
- 2020–2024
Principal investigator · Completed · Phase 1
Kathy Miller
- 2018–2020
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Principal investigator · Completed · Phase 1
Kathy Miller
- 2017–2019
iMETX (Individualized Metabolic RX): a Pilot Study
Principal investigator · Completed
Indiana University